Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

e-Poster Display Session

55P - MOREL: Multicenter observational study on treatment and PD-L1 testing in patients (pts) with newly diagnosed stage IV NSCLC in Spain

Date

09 Dec 2020

Session

e-Poster Display Session

Presenters

Belén Rubio-Viqueira

Citation

Annals of Oncology (2020) 31 (suppl_7): S1428-S1440. 10.1016/annonc/annonc391

Authors

B. Rubio-Viqueira1, M. Majem Tarruella2, M.E. Lazaro3, S. Vazquez Estevez4, J.F. Cordoba-Ortega5

Author affiliations

  • 1 Hospital Universitario Quirónsalud Madrid, Pozuelo de Alarcón/ES
  • 2 Hospital de la Santa Creu i Sant Pau, Barcelona/ES
  • 3 Hospital Universitario Alvaro Cunqueiro, Vigo/ES
  • 4 Hospital Xeral Calde of Lugo, Lugo/ES
  • 5 Hospital Universitario Arnau de Vilanova, Lleida/ES
More

Abstract 55P

Background

First-line treatment of advanced NSCLC has undergone a great change in recent years. The aim of MOREL is to describe patterns of clinical management of newly diagnosed stage IV NSCLC pts without targetable mutations and to characterize PD-L1 testing in Spain.

Methods

This is a multicenter, observational, retrospective study based on clinical records from 10 representative centers. Pts diagnosed in 2019 with stage IV NSCLC and no sensitizing mutations/translocations (EGFR, ALK, BRAF, ROS1) were included. Clinical management and PD-L1 diagnosis methods are described, according to demographic and clinicopathologic characteristics of the population.

Results

Two hundred ninety-seven patients were included. Overall, median age was 67 years (range: 37-89), 77.1% were male. ECOG 0, 1 or ≥2 was 27.8%, 46.4%, and 25.8%, respectively. 17.8 % had squamous NSCLC. 15.2% and 21.9% had liver and brain metastases, respectively. Data on autoimmune disease, comorbidities and systemic corticosteroids was also analyzed. PD-L1 test was performed in 287 pts (96.6%), 4.9% in centralized laboratory, with a median turnaround time of 5 days. The most used method was 22C3 pharmaDx kit (54.7%). PD-L1 TPS (<1%, 1-49% and ≥50%) account for 40.1%, 26.8%, and 32.1%, respectively. Table: 55P

N Double CT (Chemotherapy) Single agent CT IO CT + IO IO + IO
%
Overall treated population 265 53.6 1.9 26.8 14.7 2.3
Age groups
   ≤75 years 218 54.1 1.4 24.3 17 2.3
   >75 years 47 51.1 4.3 38.3 4.3 2.1
Gender
   Male 204 55.9 2 27 12.7 2
   Female 61 45.9 1.6 26.2 21.3 3.3
Smoking history
   Current/former smoker 236 54.7 1.7 26.7 14 2.1
   Never smoked 26 38.5 3.8 30.8 23.1 3.8
ECOG
   0-1 209 52.2 1 25.8 17.2 2.9
   ≥2 54 61.1 5.6 27.8 5.6 0
NSCLC histological subtype
   Squamous 50 68 2 24 2 4
   Non squamous 215 49.8 1.9 27.4 17.7 2.3
Brain Metastases
   Yes 59 54.2 1.7 22 18.6 3.4
   No 206 53.4 1.9 28.2 13.6 2.4
PD-L1 TPS (%)
   <1 100 73 4 1 21 1
   1-49 70 74.3 1.4 5.7 14.3 2.9
   ≥50 85 12.9 0 76.5 7.1 3.5
   Not evaluable 3 66.7 0 0 0 33.3

Conclusions

The implementation of PD-L1 testing is feasible in the clinical practice and seems to guide treatment decisions with IO, according to the regulation in Spain.

Legal entity responsible for the study

Merck Sharp & Dohme.

Funding

Merck Sharp & Dohme Spain.

Disclosure

B. Rubio-Viqueira: Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche; Advisory/Consultancy, Non-remunerated activity/ies: Lilly; Advisory/Consultancy, Speaker Bureau/Expert testimony, Non-remunerated activity/ies: Boehringer Ingelheim. M. Majem Tarruella: Advisory/Consultancy, Travel/Accommodation/Expenses: Merck Sharp & Dohme; Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy, Non-remunerated activity/ies: Boehringer Ingelheim; Advisory/Consultancy, Non-remunerated activity/ies: AstraZeneca; Advisory/Consultancy, Non-remunerated activity/ies: Roche; Advisory/Consultancy: Kyowa Kyrin; Non-remunerated activity/ies: Pierre Fabre; Advisory/Consultancy: Takeda; Non-remunerated activity/ies: Bayer. M.E. Lazaro: Travel/Accommodation/Expenses, Non-remunerated activity/ies: Merck Sharp & Dohme; Advisory/Consultancy, Travel/Accommodation/Expenses, Non-remunerated activity/ies: Roche; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy, Speaker Bureau/Expert testimony: Bristol Myers Squibb; Advisory/Consultancy, Speaker Bureau/Expert testimony, Non-remunerated activity/ies: AstraZeneca; Advisory/Consultancy: Eusa Pharma; Advisory/Consultancy, Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Pfizer; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Astellas; Speaker Bureau/Expert testimony: Janssen; Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Ipsen; Travel/Accommodation/Expenses: Lilly. S. Vazquez Estevez: Advisory/Consultancy, Non-remunerated activity/ies: Merck Sharp & Dohme; Advisory/Consultancy, Research grant/Funding (institution): Bristol Myers Squibb; Advisory/Consultancy, Non-remunerated activity/ies: Boehringer Ingelheim; Advisory/Consultancy, Non-remunerated activity/ies: AstraZeneca; Advisory/Consultancy, Travel/Accommodation/Expenses, Non-remunerated activity/ies: Roche; Advisory/Consultancy: Kyowa Kyrin; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Takeda; Travel/Accommodation/Expenses: Bayer. J.J. Garcia Gonzalez: Advisory/Consultancy, Non-remunerated activity/ies: Merck Sharp & Dohme; Advisory/Consultancy: Boehringer Ingelheim; Advisory/Consultancy: AstraZeneca; Advisory/Consultancy, Non-remunerated activity/ies: Bristol Myers Squibb; Advisory/Consultancy, Non-remunerated activity/ies: Roche; Advisory/Consultancy, Non-remunerated activity/ies: Lilly; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Novartis; Advisory/Consultancy: Pierre Fabre; Advisory/Consultancy: Sanofi. C. Gonzalez Arenas: Full/Part-time employment: Merck Sharp & Dohme. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.